Amsterdam, The Netherlands – June 19, 2026 – The life sciences sector stands on the precipice of a profound transformation, driven by the burgeoning integration of digital health tools designed to capture Real-World Evidence (RWE). This new era promises to unlock unprecedented insights into the day-to-day efficacy and impact of drugs and devices, potentially revolutionizing patient care and accelerating drug development. However, experts convened at the HLTH Europe 2026 conference have underscored that the path to realizing this revolutionary potential is fraught with significant systemic challenges that require urgent attention and collaborative action.
The increasing acknowledgment within pharmaceutical companies of the value of RWE is fueling this digital shift. Unlike traditional clinical trial data, which often provides a snapshot of a patient’s condition at specific intervals, RWE derived from digital health tools offers a continuous, dynamic stream of information. This allows for a more nuanced understanding of how treatments perform in the messy, multifaceted reality of everyday life, enabling healthcare providers to tailor care with greater precision and developers to refine their offerings based on tangible patient outcomes.
At the forefront of these discussions at HLTH Europe 2026, held in Amsterdam from June 15-18, was the imperative to harness the power of RWE. Dedicated panel sessions explored how this wealth of data could be leveraged to improve patient outcomes, enhance drug development pipelines, and elevate the healthcare sector’s capacity for personalized medicine. Yet, alongside the optimistic projections, a clear consensus emerged: while the tools are rapidly evolving, the underlying infrastructure, regulatory frameworks, and industry mindsets are lagging, creating substantial barriers to widespread adoption and effective utilization.
Digital Health: Ushering in a New Era of RWE Collection
The proliferation of digital health technologies, encompassing everything from sophisticated wearable sensors to ubiquitous health applications, is fundamentally reshaping how health data is gathered. This digital wave is moving the industry away from the limitations of episodic data, which offers only a fragmented view of a patient’s health journey, towards a continuous, real-time understanding. This shift is crucial for capturing the nuances of chronic disease management, treatment adherence, and the subtle, long-term effects of interventions.
Lisa Lehmann, Director of Research at Verily, articulated a compelling vision for the future, emphasizing that continuous data streams from digital health technologies will find application in a multitude of new contexts. The success of devices like Continuous Glucose Monitors (CGMs) for diabetics, which empower proactive condition management without the need for frequent, invasive procedures, serves as a powerful precedent. Lehmann noted, "Companies that can build products that providers trust and that translate data into actionable insights will ultimately lead this space."
Complementing this perspective, Abhishek Pratap, Head of Medicine, Digital Health Technologies at Boehringer Ingelheim, highlighted the indispensable role of user-centricity in the successful implementation of RWE strategies. He stressed that the design and deployment of these digital tools must prioritize the needs and experiences of both patients and healthcare professionals to ensure genuine engagement and data utility.
Making Data a Core Focus: From Information to Insight
The critical need to embed data at the heart of all healthcare decision-making was a recurring theme throughout the conference. Ben Taylor, CFO and President of Recursion, forcefully argued for a fundamental attitudinal shift within the industry. "It doesn’t matter if you’re talking about chemistry, biology, patient selection, or clinical trial design – data should be the foundation of decision-making, rather than a tool you add on to a process," he asserted. "This is the attitude shift we need across the industry."
However, Taylor also pointed to a significant impediment: the generally low quality and inconsistent nature of currently available data, often not being optimized for machine learning (ML) applications. The generation of more consistently annotated data, compatible with artificial intelligence (AI) algorithms, is deemed essential for unlocking accurate insights and driving progress. This requires a concerted effort to standardize data collection protocols and ensure interoperability across diverse digital health platforms.
David Thornton, President of Genomics, underscored the importance of democratizing access to the insights derived from RWE. He believes that achieving this will necessitate a greater reliance on the analytical power of AI models to interpret complex datasets. This, in turn, calls for an "all-in" approach to AI adoption and integration across all levels of an organization, fostering a culture that embraces data-driven discovery.
Yet, the enthusiasm for data must be tempered with pragmatism. Richard Cassidy, SVP Rx+ Business Accelerator at Astellas, offered a critical perspective from the front lines of clinical practice. "Physicians don’t usually want more data," he stated candidly. "They’re overburdened, and they don’t need it. What they want is information that directly helps them to make the best, most robust decision for a patient." This emphasizes that the value of RWE lies not in the sheer volume of data collected, but in its ability to be distilled into concise, actionable intelligence that directly informs clinical judgment.
Cassidy stressed the necessity of understanding the specific decisions that RWE is intended to influence, coupled with a deep comprehension of individual patient needs and the practical requirements of physicians in managing those patients. Yajing Zhu, Director of Computational RWE at Novo Nordisk, echoed this sentiment, urging sponsors to pose the "right questions" to ensure that their RWE initiatives are truly impactful and "move the needle" in meaningful ways.
Systemic Change: The Lagging Frontier
The transition towards continuous RWE collection, powered by digital health, necessitates a fundamental overhaul of existing regulatory and operational frameworks. Richard Cassidy issued a stark warning: "If you have an incorporated or standalone digital therapy, the data set produced by it is continually growing, evolving, and changing." Current regulations, he explained, are largely designed to evaluate fixed datasets submitted for approval, creating a mismatch with the dynamic nature of data generated by digital health interventions. This discrepancy poses a significant hurdle for the integration of these evolving datasets into regulatory submissions and clinical decision-making processes.
Lisa Lehmann concurred, highlighting the need to establish clear benchmarks for what constitutes "decision-grade" evidence on a broad scale. This involves not only defining the technical quality of the data but also developing standardized methodologies for its validation and interpretation in a clinical context. The challenge lies in bridging the gap between the raw data generated by digital tools and the robust, reliable evidence required for regulatory approval and widespread clinical adoption.
Furthermore, Lehmann pointed to what she termed "foundational challenges" related to infrastructure. This encompasses the development of robust technological architectures that can securely and efficiently manage vast quantities of real-world data, as well as the creation of seamless pathways for translating digital health technologies into practical, real-world applications that demonstrably improve patient outcomes. Without addressing these systemic issues, the revolutionary potential of RWE risks remaining largely untapped, confined to pilot projects and niche applications rather than becoming a cornerstone of mainstream healthcare delivery.
Supporting Data: The Growing Landscape of Digital Health Adoption
The adoption of digital health tools is no longer a nascent trend but a rapidly accelerating phenomenon. Global spending on digital health solutions is projected to surpass $300 billion by 2027, driven by increasing consumer demand for personalized health management and a growing recognition by healthcare providers of the potential for efficiency gains and improved patient engagement.
Wearable devices, such as smartwatches and fitness trackers, are now capable of monitoring a wide array of physiological parameters, including heart rate, sleep patterns, activity levels, and even blood oxygen saturation. These devices, when integrated with secure data platforms, can provide a continuous stream of objective health data that complements traditional patient-reported outcomes.
Mobile health applications (mHealth) are also playing a pivotal role. From medication adherence reminders and symptom trackers to mental wellness support and chronic disease management platforms, mHealth apps empower patients to take a more active role in their own health. The data collected through these applications can offer valuable insights into treatment adherence, disease progression, and the impact of lifestyle factors on health outcomes.
The integration of these disparate data sources into comprehensive RWE profiles presents both an opportunity and a challenge. The opportunity lies in the creation of a holistic view of patient health that transcends the limitations of single-source data collection. The challenge, however, lies in ensuring data interoperability, standardization, and robust security protocols to protect sensitive patient information.
Official Responses and Industry Initiatives: A Call to Action
While regulatory bodies are beginning to adapt to the evolving landscape of RWE, the pace of change is a subject of ongoing debate. The U.S. Food and Drug Administration (FDA), for instance, has been actively developing frameworks and guidance for the use of RWE in regulatory decision-making, recognizing its potential to support drug development and post-market surveillance. Similar initiatives are underway in Europe and other key global markets.
However, the conference discussions underscored that a more proactive and collaborative approach is needed from all stakeholders. Pharmaceutical companies are increasingly investing in RWE capabilities, forming strategic partnerships with technology providers and academic institutions. This includes developing in-house expertise in data science, AI, and digital health implementation.
Furthermore, industry consortia and multi-stakeholder alliances are emerging to address the systemic challenges. These groups are focused on developing common data standards, ethical guidelines for data use, and best practices for the collection and analysis of RWE. The goal is to foster an ecosystem where RWE can be reliably generated, rigorously evaluated, and effectively translated into tangible improvements in patient care.
Implications: Reshaping the Future of Healthcare
The successful integration of digital health tools for RWE generation has profound implications for the future of healthcare:
- Accelerated Drug Development: RWE can provide valuable insights into the effectiveness and safety of drugs in diverse patient populations, potentially streamlining clinical trial design, identifying unmet needs, and accelerating the path to market for new therapies.
- Personalized Medicine: Continuous RWE allows for a deeper understanding of individual patient responses to treatments, enabling healthcare providers to tailor therapeutic strategies with unprecedented precision, leading to improved outcomes and reduced adverse events.
- Enhanced Patient Engagement and Empowerment: Digital health tools can empower patients to actively participate in their own health management, fostering greater adherence to treatment plans and a more proactive approach to well-being.
- Improved Public Health Surveillance: The aggregation of RWE can provide real-time insights into disease trends, treatment patterns, and the impact of public health interventions, enabling more effective and responsive public health strategies.
- Value-Based Healthcare: By providing objective evidence of treatment effectiveness in real-world settings, RWE can support the shift towards value-based healthcare models, where reimbursement is tied to patient outcomes rather than service volume.
The journey towards fully realizing the transformative potential of RWE through digital health is complex and requires a concerted, collaborative effort. While the technological advancements are undeniable, addressing the systemic challenges related to data quality, standardization, regulatory frameworks, and ethical considerations will be paramount. The insights shared at HLTH Europe 2026 serve as a critical call to action: the revolution in healthcare is within reach, but it demands a unified commitment to building the robust infrastructure and supportive ecosystem necessary to harness its full promise.
About the Author
